Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | CYP2A13 | Q16696 | 5/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | TYMP | P19971 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5147215 | 0.86 | ALOX15 (0.41) | ALOX15MEN1KMT2AHTT | |
| SCHEMBL9984380 | 0.82 | HRH3 (0.40) | HRH3ALDH1A1KMT2AHTT | |
| SCHEMBL10801520 | 0.81 | HRH3 (0.43) | HRH3ALOX15ALDH1A1KMT2AHTT | |
| SCHEMBL24135409 | 0.79 | SIGMAR1 (0.44) | CXCR4HRH3MEN1ALDH1A1KMT2A | |
| SCHEMBL6270109 | 0.75 | CXCR4 (0.53) | CXCR4HRH3CYP2C9ALOX15HSD17B10 | |
| SCHEMBL6555500 | 0.70 | NPC1 (0.47) | CXCR4HRH3CYP2C9ALOX15HSD17B10 | |
| SCHEMBL13156073 | 0.70 | SMN1; SMN2 (0.46) | CXCR4HRH3CYP2C9ALOX15HSD17B10 | |
| SCHEMBL19145771 | 0.70 | SMN1; SMN2 (0.47) | CXCR4HRH3CYP2C9ALOX15HSD17B10 | |
| Amitrole SCHEMBL7215486 | 0.70 | KEAP1 (0.43) | HRH3ALOX15ALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL3222601 | 0.69 | GAA (0.46) | MEN1ALDH1A1KMT2ASMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1085875-A1 | USE OF A NK-1 RECEPTOR ANTAGONIST FOR TREATING PSYCHIATRIC DISORDERS | MERCK SHARP & DOHME LTD. (GB) | 2001-03-28 | — | — | EP | claimed |
| WO-1999064010-A1 | USE OF A NK-1 RECEPTOR ANTAGONIST FOR TREATING PSYCHIATRIC DISORDERS | MERCK SHARP & DOHME LIMITED (GB) | 1999-12-16 | — | — | WO | claimed |
| US-7320994-B2 | Triazole derivatives as tachykinin receptor antagonists | ELI LILLY AND COMPANY (US) | 2008-01-22 | — | — | US | disclosed |
| EP-1807102-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF OBESITY AND SEXUAL DYSFUNCTION | Merck & Co., Inc. (US) | 2007-07-18 | — | — | EP | disclosed |
| WO-2006049933-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF OBESITY AND SEXUAL DYSFUNCTION | MERCK & CO., INC. (US) | 2006-05-11 | — | — | WO | disclosed |
| US-20050239786-A1 | Triazole derivatives as tachykinin receptor antagonists | ELI LILLY COMPANY (US) | 2005-10-27 | — | — | US | disclosed |
| EP-1099702-B1 | Substituted morpholine derivatives and their use as therapeutic agents | MERCK SHARP & DOHME (GB) | 2004-10-06 | — | — | EP | disclosed |
| EP-1462450-A1 | Substituted morpholine derivatives and their use as therapeutic agents | MERCK SHARP & DOHME LTD. (GB) | 2004-09-29 | — | — | EP | disclosed |
| EP-0737192-B1 | SUBSTITUTED MORPHOLINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME (GB) | 2001-10-31 | — | — | EP | disclosed |
| CN-1067683-C | Substituted morpholine derivatives and their use as therapeutic agents | MERK SHARP & DOHME LTD (GB) | 2001-06-27 | — | — | CN | disclosed |
| EP-1099702-A1 | Substituted morpholine derivatives and their use as therapeutic agents | MERCK SHARP & DOHME LTD. (GB) | 2001-05-16 | — | — | EP | disclosed |
| EP-1085875-A1 | USE OF A NK-1 RECEPTOR ANTAGONIST FOR TREATING PSYCHIATRIC DISORDERS | MERCK SHARP & DOHME LTD. (GB) | 2001-03-28 | — | — | EP | disclosed |
| EP-1085874-A1 | USE OF A NK-1 RECEPTOR ANTAGONIST FOR TREATING SEXUAL DYSFUNCTIONS | MERCK SHARP & DOHME LTD. (GB) | 2001-03-28 | — | — | EP | disclosed |
| WO-1999064008-A1 | USE OF A NK-1 RECEPTOR ANTAGONIST FOR TREATING SEXUAL DYSFUNCTIONS | MERCK SHARP & DOHME LIMITED (GB) | 1999-12-16 | — | — | WO | disclosed |
| WO-1999064010-A1 | USE OF A NK-1 RECEPTOR ANTAGONIST FOR TREATING PSYCHIATRIC DISORDERS | MERCK SHARP & DOHME LIMITED (GB) | 1999-12-16 | — | — | WO | disclosed |
| US-5612337-A | ANALGESIC COMPOUNDS FOR PRODRUGS | MERCK SHARP & DOHME LIMITED (GB) | 1997-03-18 | — | — | US | disclosed |
| CN-1139927-A | Substituted morpholine derivatives and their use as therapeutic agents | MERK SHARP & DOHME LTD (GB) | 1997-01-08 | — | — | CN | disclosed |
| EP-0122693-B1 | ANTIFUNGAL DI(AZOLYL)PROPANOL DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1987-07-08 | — | — | EP | disclosed |
| US-4625036-A | Antifungal azole compounds | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1986-11-25 | — | — | US | disclosed |
| EP-0122693-A1 | Antifungal di(azolyl)propanol derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1984-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239786-A1 | Triazole derivatives as tachykinin receptor antagonists | TACR1, TACR2, BDKRB1 | CXCR4 540/4885HRH3 21/4885CYP2C9 2020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.